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Abstract
Background: In comparative pathology, canine mammary tumours have special interest because
of their similarities with human breast cancer. Mixed tumours are uncommon lesions in the human
breast, but they are found most frequently in the mammary gland of the female dogs and in the
human salivary glands. The aim of the study was to compare clinical, morphological and
immunohistochemical features of human salivary and canine mammary gland mixed tumours, in
order to evaluate the latter as an experimental model for salivary gland tumours.
Methods: Ten examples of each mixed tumour type (human pleomorphic adenoma and
carcinomas ex-pleomorphic adenomas and canine mixed tumour and metaplastic carcinoma) were
evaluated. First, clinical and morphologic aspects of benign and malignant variants were compared
between the species. Then, streptavidin-biotin-peroxidase immunohistochemistry was performed
to detect the expression of cytokeratins, vimentin, p63 protein, estrogen receptor, β-catenin, and
E-cadherin.
Results: After standardization, similar age and site distributions were observed in human and
canine tumours. Histological similarities were identified in the comparison of the benign lesions as
well. Metaplastic carcinomas also resembled general aspects of carcinomas ex-pleomorphic
adenomas in morphological evaluation. Additionally, immunohistochemical staining further
presented similar antigenic expression between lesions.
Conclusion: There are many similar features between human salivary and canine mammary gland
mixed tumours. This observation is of great relevance for those interested in the study and
management of salivary gland tumours, since canine lesions may constitute useful comparative
models for their investigations.
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Animal models have been widely used to investigate sev-
eral forms of human neoplasias. Because of centuries of
coexistence with humans in the same environment, dogs
are of particular interest as they provide important evolu-
tionary information. In addition, both species show great
genotypic similarities [1]. Thus, spontaneous tumours of
canine mammary glands have been proposed as compar-
ative models for the study of human breast cancer, since
these lesions share epidemiological, clinical, behavioural
and antigenic features [2-5].
There is also a well-known relationship between the inci-
dence of human mammary and salivary glands tumours
[6-9]. Morphological similarities have been described
between certain tumours of salivary glands and breast
neoplasias such as those existing between polymorphous
low-grade adenocarcinoma and invasive lobular carci-
noma [10], between acinic cell carcinoma and invasive
secretory carcinoma [11], and between epithelial-myoep-
ithelial carcinoma and adenomyoepithelioma [12]. Duc-
tal carcinomas [13,14], adenoid cystic carcinomas and
mixed tumours with similar patterns may be found in
both organs [15,16].
Mixed tumours are unusual lesions in the human breast
[17], but they are frequent in both human salivary and
canine mammary glands [18-20]. In a comparative evalu-
ation of the available literature, pleomorphic adenoma
(PA) and its malignant counterpart, the carcinomas ex-
pleomorphic adenomas (Ca ex-PA) have several interest-
ing similarities to benign mixed tumours (MT) and to
metaplastic carcinomas (MC) of canine mammary glands.
First, all of them are derived from exocrine glands, which
depict similar tissue architecture. Next, with few varia-
tions, both are microscopically characterized by a mixture
of ductal and myoepithelial elements intermingling an
apparently mesenchymal stroma of variable constitution
[18-20]. In addition, malignant transformation is
acknowledged for both for human PA and canine MT, par-
ticularly in lesions with long evolution and frequent
recurrences [20-25]. In spite of these similar aspects, to the
best of our knowledge no specific comparative investiga-
tion between human salivary and canine mammary
glands tumours is available.
Thus, the present work aimed to perform objective mor-
phological microscopic comparison between mixed
tumours derived from human salivary and canine mam-
mary glands, as well as to evaluate the immunohisto-
chemical expression of some relevant antigens in order to
characterize these two types of neoplastic alterations.
Methods
Samples
Ten samples of PA and 10 of Ca ex-PA were obtained from
the Department of Pathology of School of Medicine, Fed-
eral University of Minas Gerais (UFMG, Belo Horizonte,
Minas Gerais, Brazil), A. C. Camargo Cancer Hospital
(São Paulo, São Paulo, Brazil), and the National Cancer
Institute (Rio de Janeiro, Rio de Janeiro, Brazil). Ten sam-
ples of MT and 10 of MC of mammary glands of dogs
without defined breed were obtained from the records of
the Laboratory of Comparative Pathology, Biological Sci-
ences Institute, UFMG. Ca ex-PA diagnosis was restricted
to cases with clinical features (such us a previous benign
tumour excised from a site in which recurrent malignant
tumour), and/or histological evidence of arising in or
from a benign lesion (identification of at least a focus
benign tumour) [18]. The clinical analyses of the tumours
studied are summarized in Tables 1, 2, 3, 4. The malignant
components of Ca ex-PA were further identified and sub-
typed according to World Health Organization (WHO)
and Armed Forces Institute of Pathology (AFIP) criteria
[18,26] and are summarized in Table 2.
All samples were formalin-fixed, paraffin-embedded, and
new histological sections were independently reviewed by
two experienced observers to confirm the diagnosis. Clin-
ical and demographic data (age, gender, affected salivary
or mammary gland) from affected individuals were
retrieved from medical and veterinary charts.
Immunohistochemistry
To further compare tumours, immunohistochemical
assays were carried out to detect antigens related to cellu-
lar differentiation (cytokeratins, vimentin, and p63),
adhesion (E-cadherin and β-catenin), and hormonal sta-
tus (estrogen receptor), which have been shown to be rel-
evant for the study of human salivary and breast cancer
[27-36]. Streptavidin-biotin-peroxidase technique was
used, employing the antibodies described in Table 5.
Briefly, 3 μm thick histological sections were deparaffin-
Table 1: Clinical characterization of human salivary glands 
pleomorphic adenomas. (M – male; F – female)
Case Age Gender Gland
1 30 M minor (lip)
2 35 F parotid
3 42 M parotid
4 53 F parotid
5 29 F parotid
6 51 F parotid
7 32 F parotid
8 39 F submandibular
9 58 M parotid
10 27 M parotidPage 2 of 9
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trations. Next, they were submitted to antigenic retrieval
(Target Retrieval Solution, pH 6.0, DakoCytomation,
Carpinteria, USA) and endogenous peroxidase blocking
(3% hydrogen peroxide in methanol). After incubation
with primary antibodies (Table 5) and amplification
(Ultra Vision Large Volume Detection System, Lab Vision,
Fremont, USA), the reaction was revealed with diami-
nobenzidine as chromogen and Mayer haematoxylin as
contrast. As positive controls, sections of normal human
salivary and mammary glands with previously recognized
positivity for the antigens studied were used. Substitution
of primary antibody for normal human serum constituted
the negative control.
Finally, morphological analysis of staining was per-
formed, and then a semiquantitative protocol was
employed to segregate the cases. For this latter purpose the
entire available tumoural tissue in the sections was evalu-
ated. Next, it was determined whether the relative number
of positive neoplastic cells was superior ("positive cases")
or inferior ("negative cases") to 5% (for the analysis of
p63 and estrogen receptor) [37,38] or 10% (cytokeratins,
vimentin, E-cadherin, β-catenin) [29,32] from all of the
neoplastic cells in the histological sections evaluated.
Statistical analysis
Frequency of positive immunostaining between the four
groups of lesions was evaluated by Fisher's exact test with
values of p < 0.05 considered statistically significant.
Probability of α-error inferior to 5% was confirmed to be
significant.
Results
In both species it was observed that the benign tumours
occur in the younger individuals' group, while the malig-
nant tumours are more frequent in older individuals'
group. A slight predominance of female patients (six
cases) was observed for PA, while a homogeneous distri-
bution was observed among those patients with Ca ex-PA.
In dogs, all lesions affected females.
Histomorphological comparative illustrations are exem-
plified in Figure 1. In general, both benign tumours pre-
sented formation of ductal structures and also cells with
myoepithelial features, arranged in solid aggregations,
Table 5: Primary antibodies, resources and dilutions used in 
immunohistochemical assays
Antibody Clone Resource Dilution
Anti-pan-cytokeratin NCL-AE1/AE3 Novocastra 1:100
Anti-vimentin V9 DAKO 1:50
Anti-p63 4A4 Santa Cruz 1:100
Anti-β-catenin E-5 Santa Cruz 1:400
Anti-E-cadherin 4A2C7 Zymed 1:40
Anti-estrogen receptor CC4–5 Novocastra 1:50
Table 3: Clinical characterization of benign mixed tumours of 
canine mammaryglands
Case Age Gender Localization
1 5 F Inguinal
2 7 F Thoracic-cranial
3 9 F Abdominal-caudal
4 4 F Abdominal-caudal
5 6 F Thoracic-cranial
6 3 F Inguinal
7 7 F Abdominal-caudal
8 5 F Inguinal
9 7 F Inguinal
10 8 F Inguinal
Table 2: Clinical and histological subtypes of human salivary 




Gender Gland Histological 
Subtype
1 33 F minor (palate) adenocarcinoma NOS
2 22 F submandibular adenocarcinoma NOS
3 71 M parotid undifferentiated 
carcinoma
4 53 F minor (palate) myoepithelial 
carcinoma
5 43 M Parotid myoepithelial 
carcinoma
6 02 M parotid myoepithelial 
carcinoma
7 65 F parotid adenoid cystic 
carcinoma (solid)
8 70 M minor (palate) adenoid cystic 
carcinoma (tubular)
9 92 F submandibular polymorphous low-
grade adenocarcinoma
10 66 M parotid mucoepidermoid 
carcinoma
Table 4: Clinical characterization of malignant mixed tumours of 
canine mammary glands
Case Age Gender Localization
1 7 F Thoracic-cranial
2 13 F Thoracic-caudal
3 5 F Abdominal-cranial
4 8 F Inguinal
5 9 F Thoracic-caudal
6 8 F Inguinal
7 9 F Inguinal
8 9 F Thoracic-cranial
9 6 F Thoracic-cranial
10 4 F Abdominal-cranialPage 3 of 9
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a predominantly myxoid or myxo-chondroid matrix. MC
were observed to be histomorphologically similar to the
adenocarcinoma NOS (not-otherwise specified) or to
undifferentiated carcinoma-type Ca ex-PA, since both
were infiltrative lesions with malignant degeneration
areas, characterized by cell pleomorphism (ovoid to poly-
hedral cells with clear to hyaline cytoplasm), and hyper-
chromatic or vesiculated nuclei with conspicuous
nucleoli.
Immunohistochemical assays displayed positive cytoplas-
mic localization of cytokeratins in all neoplastic cells from
all lesions. Vimentin was identified in the cytoplasm of
non-luminal cells of ductal formations, in plasmacytoid
and spindle cells of PA and canine MT, in all MC cells, and
was identified diffusely in Ca ex-PA with myoepithelial
differentiation (those which the malignant component
was described as myoepithelial, adenoid cystic, and poly-
morphous low-grade adenocarcinomas).
All PA presented positive p63 nuclear immunolocaliza-
tion in neoplastic luminal, plasmacytoid and spindle
cells, while p63 was found in only five samples of Ca ex-
PA (two samples with diagnosis of myoepithelial carci-
noma, two with adenoid cystic carcinomas, and one with
undifferentiated carcinoma). All canine MT and MC
depicted positive p63 expression, in a similar fashion to
that seen in PA, while the malignant lesion had less posi-
tive cells and these presented less intense reaction (Figure
2). The decrease in immunopositivity frequency in Ca ex-
PA was significantly different regarding all the other
groups (p < 0.05).
β-catenin expressions in neoplastic epithelial cells of both
PA of human salivary gland and MT of canine mammary
glands have shown to be similar in location, to the expres-
sion in normal glandular parenchyma (membrane and/or
cytoplasmic). Membrane and cytoplasmic β-catenin
immunolocalization was especially frequent in cells of
ductal formations in these benign tumours. In malignant
lesions, nuclear expression of this protein was also identi-
fied (Figure 3). No β-catenin expression was observed in
highly atypical areas of malignant tumours of both species
or in those with rich myxo-chondroid stroma.
Histopathological aspects of benign and malignant mixed tumours of human salivary and canine mammary glands by haematox-ylin and e sin (HE) stain; original magnificatio , 10×F gure 1
Histopathological aspects of benign and malignant mixed tumours of human salivary and canine mammary glands by haematox-
ylin and eosin (HE) stain; original magnification, 10×. (A) Pleomorphic adenoma in human salivary gland; (B) Mixed tumour in 
canine mammary gland; (C) Carcinoma ex-pleomorphic adenoma in human salivary gland; (D) Metaplastic carcinoma in canine 
mammary gland.Page 4 of 9
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tumours of both species presented a similar linear mem-
brane expression to that of normal gland parenchyma.
Malignant neoplasias depicted less intense expression,
which was also related to poor cell differentiation (Figure
4).
Estrogen receptor expression was not identified in
tumours from the human salivary gland, while all the
canine mammary tumours presented immunoreactivity
for this marker (p < 0.05).
Discussion
The study of animal tumours may provide data to
improve the understanding of similar lesions in humans,
as well as tumour aetiology and development [39]. To
date, there is not a universally accepted animal model for
neoplastic pathology investigations. Transgenic mice, for
instance, have received criticism as some of these animals
are refractory to the development of certain types of
tumours despite presentation of the same genetic lesion
[40]. Animal cell culture is also an imperfect comparative
model, as many of the events associated with carcinogen-
esis variably depend on a host [41]. One of the great
advantages of canine breast model is that tumours are
spontaneous in this organ. As its clinical evolution is nat-
ural, genetic and morphophysiological aspects may be
better compared with some aspects of the human species
[42].
Dogs represent a remarkable incidence of neoplasia devel-
opment, usually associated with environmental exposure
to important carcinogens for humans [1,43]. Tumours
effecting the mammary glands, especially in females, are
among the most frequent tumours observed in dogs.
Finally, mixed tumours are one of the most frequent neo-
plasias in dogs [19] with remarkable features in common
with human salivary gland tumours, justifying the investi-
gation of other possible similarities between lesions of
these two species.
The present study has confirmed that canine mammary
gland MT and MC share some clinical characteristics with
human salivary gland PA and Ca ex-PA, including age of
emergence and several histopathological aspects. We have
also demonstrated that commercially available antibodies
for the study of human neoplasias are functional to detect
antigenic expression in canine lesions. Moreover, similar
Immunohistochemical aspects of p63 antigen stain; original magnification, 40×Figure 2
Immunohistochemical aspects of p63 antigen stain; original magnification, 40×. (A) Pleomorphic adenoma in human salivary 
gland; (B) Mixed tumour in canine mammary tumour; (C) Carcinoma ex-pleomorphic adenoma in human salivary gland; (D) 
Metaplastic carcinoma in canine mammary gland. Note myoepithelial p63-negative cells in malignant tumours (arrows).Page 5 of 9
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enin, and E-cadherin) were identified between the lesions,
suggesting common pathogenetic mechanisms in the his-
togenesis of these tumours.
Vimentin and the pool of cytokeratins detected by the
monoclonal antibody AE1/AE3 depicted parallel immu-
nolocalization pattern, confirming the utility of this anti-
gen to biologically characterize tumoural components.
p63 immunolocalization was restricted to cells with
myoepithelial morphological features in PA, and to
lesions of myoepithelial differentiation in Ca ex-PA, albeit
the less intense staining in the latter suggests some loss of
differentiation [44]. Similar observations were found for
canine tumours, corroborating the use of this marker to
demonstrate myoepithelial cells in both species. How-
ever, the analysis of the antigenic behaviour in tumours of
both species is hindered by the fact that p63 possesses two
different isoforms (TAp63 and ΔNp63) with opposite
functions, being responsible for cell-cycle arrest and cell
proliferation, respectively [45]. Clone 4A4, used in our
study, recognizes all isoforms. It remains to be further
evaluated by future works.
The expression of cell adhesion relating β-catenin and E-
cadherin proteins was also similar in both species. In PA
and canine MT, β-catenin and E-cadherin presented with
predominantly membrane expression. β-catenin expres-
sion in MC and Ca ex-PA was either cytoplasmic/nuclear,
or only nuclear, suggesting that changes in antigenic loca-
tion may be related to the induction of gene transcription
linked to cell proliferation in malignant tumours
[34,35,45]. In addition, the loss of β-catenin and E-cad-
herin membrane expression may be associated with more
aggressive tumour characteristics such as invasiveness and
metastasis [46-49].
The most outstanding difference in antigenic expression
was related to estrogen receptor. ER immunostaining was
observed in all canine lesions, and it was not detected in
any human neoplasia evaluated. Several previous studies
showed the presence of ER in canine mammary tumours,
suggesting this protein participates in lesion formation
[50-52]. The lack of immunolocalization in salivary gland
Immunohistochemical aspects of β-catenin antigen stain; original magnification, 40×Figure 3
Immunohistochemical aspects of β-catenin antigen stain; original magnification, 40×. (A) Pleomorphic adenoma in human sali-
vary gland with membrane and cytoplasmic β-catenin stain; (B) Mixed tumour in canine mammary tumour with membrane and 
cytoplasmic β-catenin stain; (C) Carcinoma ex-pleomorphic adenoma in human salivary gland showing β-catenin nuclear stain 
(arrows); (D) Metaplastic carcinoma in canine mammary gland showing β-catenin nuclear stain (arrows).Page 6 of 9
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possible explanation would be the very low level expres-
sion of this protein [56], with an mRNA transcription
being observed, which was shown by the study of Lei-
mola-Virtanen et al. [57], or difficulties in recognition of
epitopes through immunohistochemistry. In this work,
the absence of ER expression in human salivary gland
tumours suggests that these lesions not very responsive to
estrogen, in contrast to the lesions in dogs, but further
studies should be carried out to better define the role this
protein in salivary gland tumorigenesis.
Conclusion
In the present work, some clinical, histopathological and
antigenic similarities were confirmed between mixed-type
tumours from human salivary and canine mammary
glands. These data could suggest a hypothesis of similar
histogenesis between these neoplasias. More interestingly,
it encourages the use of spontaneous canine mammary
gland tumours as animal models to study human salivary
gland mixed neoplasias. However, differences were also
identified and, therefore, additional studies should be car-
ried out to better define advantages and disadvantages of
a comparative assessment between these lesions.
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